These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A case of hydroxyurea-induced transverse melanonychia. Teo RY; Tan E Int J Dermatol; 2006 Nov; 45(11):1329-30. PubMed ID: 17076717 [No Abstract] [Full Text] [Related]
3. [A new etiology of inflammatory livedo: thrombocytosis]. Lèques B; Texier L; Verdaguer S; Hoffman-Martinot R; Paulet C; Moine M Presse Med (1893); 1969 Jan; 77(3):91-2. PubMed ID: 4389318 [No Abstract] [Full Text] [Related]
4. Toxicity and side effects of hydroxyurea used for primary thrombocythemia. Randi ML; Ruzzon E; Tezza F; Luzzatto G; Fabris F Platelets; 2005; 16(3-4):181-4. PubMed ID: 16011962 [TBL] [Abstract][Full Text] [Related]
5. Neurologic manifestations of essential thrombocythemia. Ann Intern Med; 1984 Feb; 100(2):316-7. PubMed ID: 6691684 [No Abstract] [Full Text] [Related]
6. [What should follow a treatment for pruritus in thrombocytosis?]. Wollina U Dtsch Med Wochenschr; 2003 Mar; 128(12):631. PubMed ID: 12649803 [No Abstract] [Full Text] [Related]
7. [Thrombocythemia with livedo, distal gangrene and colonic pseudo-tumor due to vascular thrombosis]. Dao C; Thibierge M; Bilski-Pasquier G Nouv Presse Med; 1979 Feb; 8(6):441. PubMed ID: 554110 [No Abstract] [Full Text] [Related]
8. Philadelphia-chromosome positive thrombocythemia in a child. Mishra P; Mahapatra M; Kumar R; Dixit A; Chatterjee T; Tyagi S; Choudhry DR; Sazawal S; Choudhry VP Eur J Haematol; 2005 Sep; 75(3):262-3. PubMed ID: 16104885 [TBL] [Abstract][Full Text] [Related]
10. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Randi ML; Ruzzon E; Luzzatto G; Tezza F; Girolami A; Fabris F Haematologica; 2005 Feb; 90(2):261-2. PubMed ID: 15710584 [TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea in essential thrombocytosis. Ring T N Engl J Med; 1995 Sep; 333(12):803. PubMed ID: 7643900 [No Abstract] [Full Text] [Related]
12. Longitudinal melanonychia in a patient with essential thrombocytosis under treatment with hydroxyurea. Clerico R; Corsetti P; Ambrifi M; Paolino G; Rossi MR; Bottoni U; Calvieri S Acta Dermatovenerol Croat; 2012; 20(4):281-3. PubMed ID: 23317494 [No Abstract] [Full Text] [Related]
13. Hydroxyurea in essential thrombocytosis. Van Genderen PJ; Michiels JJ N Engl J Med; 1995 Sep; 333(12):802-3. PubMed ID: 7643898 [No Abstract] [Full Text] [Related]
14. New approaches to the treatment of thrombocytosis. Fruchtman S Clin Adv Hematol Oncol; 2003 Feb; 1(2):92-3. PubMed ID: 16224383 [No Abstract] [Full Text] [Related]
15. Hydroxyurea-induced leg ulcers: is macroerythrocytosis a pathogenic factor? Vélez A; García-Aranda JM; Moreno JC J Eur Acad Dermatol Venereol; 1999 May; 12(3):243-4. PubMed ID: 10461646 [TBL] [Abstract][Full Text] [Related]
17. [New therapeutic findings in venous leg pain from the angle of a skin specialist]. Brenn H Schweiz Rundsch Med Prax; 1971 Mar; 60(10):317-20. PubMed ID: 5555740 [No Abstract] [Full Text] [Related]
18. Myeloproliferative disorders in two New Jersey families. Zauber NP; Vlad LD N J Med; 1995 Aug; 92(8):530-2. PubMed ID: 7675337 [TBL] [Abstract][Full Text] [Related]
19. Longitudinal melanonychia associated with hydroxyurea therapy in a patient with essential thrombocytosis. Cohen AD; Hallel-Halevy D; Hatskelzon L; Peretz E; Halevy S J Eur Acad Dermatol Venereol; 1999 Sep; 13(2):137-9. PubMed ID: 10568495 [TBL] [Abstract][Full Text] [Related]
20. Early cutaneous lesions secondary to hydroxyurea therapy. Radaelli F; Calori R; Faccini P; Maiolo AT Am J Hematol; 1998 May; 58(1):82-3. PubMed ID: 9590156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]